ESSENCE trial,”Showed that in USA and NSTEMI, risk of death
MI or recurrent angina was lower in the enoxaprin group than in the heparin group and the need for revascularization is lower in the enoxaparin group. Give for at least 2 days.”
The goto resource for studying materials
ESSENCE trial,”Showed that in USA and NSTEMI, risk of death
MI or recurrent angina was lower in the enoxaprin group than in the heparin group and the need for revascularization is lower in the enoxaparin group. Give for at least 2 days.”